MUSTANG BIO, INC. (MBIO): Nasdaq/NYSE listing notice — Mustang Bio receives Nasdaq deficiency notice for bid price below $1.00

MUSTANG BIO, INC.

Received Nasdaq notice on April 15, 2026 for non-compliance with minimum bid price rule after 30 consecutive business days below $1.00.
Has 180-calendar day grace period until October 12, 2026 to regain compliance by closing at $1.00+ for 10 consecutive business days.
May qualify for second 180-day period if meets Nasdaq continued listing criteria and provides written notice of intent to cure.
Could face delisting if unable to regain compliance; no decision yet on specific actions to remedy deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MUSTANG BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 15, 2026, Mustang Bio, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Staff notice has no immediate effect on the listing of the Compan

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-044890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.